Pharmacology Quiz: Amiodarone
20 questions · exam conditions
0:00
AmiodaroneQuestion 1 of 20

A patient is being initiated on amiodarone. The pharmacist is providing counseling and is explaining the rationale for the recommended baseline testing.

What is the primary reason for obtaining a baseline chest X-ray and pulmonary function tests (PFTs) before starting amiodarone?

To establish a baseline for monitoring potential future pulmonary toxicity.
To ensure the patient can tolerate the mild bronchoconstriction caused by the drug.
To rule out active tuberculosis, which can be reactivated by amiodarone.
To calculate the appropriate loading dose based on the patient's vital capacity.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Amiodarone

Practice Amiodarone in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Amiodarone, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient is being initiated on amiodarone. The pharmacist is providing counseling and is explaining the rationale for the recommended baseline testing.

What is the primary reason for obtaining a baseline chest X-ray and pulmonary function tests (PFTs) before starting amiodarone?

  1. To establish a baseline for monitoring potential future pulmonary toxicity. (correct answer)
  2. To ensure the patient can tolerate the mild bronchoconstriction caused by the drug.
  3. To rule out active tuberculosis, which can be reactivated by amiodarone.
  4. To calculate the appropriate loading dose based on the patient's vital capacity.
Explanation: When you encounter questions about baseline monitoring for medications, you're being tested on your understanding of drug-specific toxicities and the rationale behind preventive monitoring strategies. Amiodarone is notorious for causing pulmonary toxicity, which can manifest as pneumonitis or pulmonary fibrosis. This adverse effect can be serious and potentially irreversible, making early detection crucial. The primary purpose of obtaining baseline chest X-rays and PFTs is to establish reference values that allow healthcare providers to detect changes over time. Without baseline measurements, it becomes nearly impossible to distinguish between pre-existing pulmonary conditions and new amiodarone-induced changes. Answer A is correct because establishing this baseline is essential for monitoring potential future pulmonary toxicity. These tests provide the reference point needed to identify early signs of lung damage during treatment. Answer B is incorrect because amiodarone doesn't typically cause bronchoconstriction as a primary mechanism. The drug's pulmonary toxicity involves inflammatory and fibrotic processes, not bronchospasm. Answer C is wrong because amiodarone doesn't reactivate tuberculosis. While the drug can cause pulmonary inflammation, this isn't related to TB reactivation, unlike immunosuppressive medications. Answer D is incorrect because amiodarone dosing isn't calculated based on vital capacity. The loading dose is typically weight-based, and PFTs aren't used for dose calculations. Remember this pattern: baseline testing before starting medications with organ-specific toxicities (like amiodarone's pulmonary effects) is almost always about establishing reference values for future monitoring, not about immediate dosing or contraindication screening.

Question 2

An 82-year-old resident of a nursing home is on a stable regimen of amiodarone 200 mg daily. Over the past year, the nursing staff has noted a distinctive, slate-gray discoloration of his skin on sun-exposed areas like his face and hands.

This dermatologic finding, while cosmetically displeasing, is primarily the result of which of the following?

  1. An IgE-mediated hypersensitivity reaction to the drug.
  2. A fixed drug eruption that signals impending systemic toxicity.
  3. Chronic subcutaneous bleeding due to platelet dysfunction.
  4. Deposition of lipofuscin and melanin in the dermis. (correct answer)
Explanation: When you encounter dermatologic side effects from chronic drug therapy, especially with distinctive pigmentation changes, you should think about drug-induced tissue deposition rather than acute allergic reactions. The slate-gray discoloration described here is classic amiodarone-induced skin pigmentation, a well-documented adverse effect of long-term therapy. This occurs because amiodarone is highly lipophilic and accumulates in tissues over time. The drug itself, along with its metabolites, gets deposited in the dermis where it stimulates melanin production and forms lipofuscin-like complexes. These deposits create the characteristic blue-gray appearance, particularly in sun-exposed areas where photosensitivity reactions enhance the process. Choice A is incorrect because this isn't an IgE-mediated hypersensitivity reaction. IgE reactions are acute, occurring within minutes to hours, and present as urticaria, angioedema, or anaphylaxis—not chronic pigmentation changes. Choice B mischaracterizes this as a fixed drug eruption. Fixed drug eruptions are localized inflammatory lesions that recur in the same location upon re-exposure to the offending drug, not diffuse pigmentation changes. Choice C incorrectly attributes the discoloration to bleeding. While amiodarone can affect coagulation, the slate-gray appearance isn't from hemosiderin deposits or bruising patterns. Choice D correctly identifies the mechanism: deposition of lipofuscin and melanin in the dermis from chronic amiodarone accumulation. Study tip: Remember that amiodarone has multiple organ toxicities due to its long half-life and tissue accumulation. When you see chronic amiodarone therapy with unusual symptoms, think "deposition and accumulation" rather than acute reactions.

Question 3

A patient was treated with amiodarone for 3 years before it was discontinued due to a transition to catheter ablation for his arrhythmia. Six weeks after his last dose, he is prescribed simvastatin 40 mg daily by a different provider. He presents two weeks later with severe myalgias.

What is the most likely explanation for the patient's myalgias?

  1. The patient is experiencing a statin-induced myopathy unrelated to his prior amiodarone use.
  2. An interaction persists because amiodarone and its active metabolite have a very long elimination half-life. (correct answer)
  3. Amiodarone has permanently altered the function of the CYP3A4 enzyme system.
  4. Catheter ablation has altered the patient's metabolism, increasing his sensitivity to statins.
Explanation: Amiodarone and its primary active metabolite, desethylamiodarone (DEA), have extremely long elimination half-lives (amiodarone ~58 days, DEA even longer). Because amiodarone is a potent inhibitor of CYP3A4 (which metabolizes simvastatin), clinically significant concentrations can persist in the body for months after discontinuation. This leads to decreased metabolism of simvastatin, increased systemic exposure, and a higher risk of myopathy. The interaction is not permanent, but it is very prolonged. The recent initiation of the statin after discontinuation of the inhibitor makes the interaction the most probable cause.

Question 4

A patient on amiodarone 400 mg daily presents for follow-up. He complains of a tremor in his hands, difficulty with balance, and a 'pins and needles' sensation in his feet. These symptoms have been progressing over the last few months.

These findings are most consistent with which amiodarone-related adverse effect?

  1. Dose-related central and peripheral neurotoxicity. (correct answer)
  2. Thyrotoxicosis-induced sympathetic overactivity.
  3. Hypotension-induced cerebral and peripheral hypoperfusion.
  4. Acute extrapyramidal symptoms from dopamine receptor blockade.
Explanation: When encountering amiodarone toxicity questions, focus on the drug's unique pharmacokinetic properties and diverse toxicity profile. Amiodarone has an extremely long half-life (weeks to months) and accumulates in tissues, making toxicity often dose-related and progressive. The constellation of symptoms here—hand tremor, balance difficulties, and peripheral neuropathy ("pins and needles")—represents classic amiodarone neurotoxicity affecting both central and peripheral nervous systems. This toxicity typically develops insidiously over months with chronic dosing, as amiodarone accumulates in neural tissues. The combination of cerebellar dysfunction (balance problems, tremor) and peripheral neuropathy is characteristic of amiodarone's dose-dependent neurotoxic effects, making option A correct. Option B (thyrotoxicosis) would present with different symptoms like palpitations, weight loss, heat intolerance, and anxiety rather than the neurological pattern described. Option C (hypotension-induced hypoperfusion) doesn't explain the specific peripheral neuropathy component and would cause more acute, diffuse symptoms rather than this progressive pattern. Option D (extrapyramidal symptoms) is incorrect because amiodarone doesn't significantly block dopamine receptors, and extrapyramidal symptoms would include rigidity, bradykinesia, and dystonia rather than tremor with balance issues and neuropathy. For amiodarone questions, remember that its toxicities are often dose-related and cumulative due to its pharmacokinetics. Key organs affected include thyroid, lungs, liver, eyes, and nervous system. Always consider the timeline—amiodarone toxicities typically develop gradually over months, not acutely.

Question 5

A 62-year-old patient on amiodarone 200 mg daily for one year presents for a routine follow-up. He reports no new symptoms. His physical exam is unremarkable. He mentions seeing faint, swirling lines in his vision, particularly when looking at a bright light, but denies any decrease in visual acuity.

What is the most appropriate interpretation and action regarding his visual symptoms?

  1. This suggests optic neuropathy; amiodarone should be discontinued immediately.
  2. These are symptoms of corneal microdeposits; reassure the patient and continue therapy. (correct answer)
  3. This is likely a cataract; refer to an ophthalmologist for surgical evaluation.
  4. These symptoms are unrelated to amiodarone; advise a neurological consultation.
Explanation: The patient is describing classic symptoms of amiodarone-induced corneal microdeposits (vortex keratopathy), which occur in the majority of patients on long-term therapy. These deposits are generally considered benign, are dose-dependent, and rarely affect visual acuity. The correct management is reassurance and continued monitoring. It is crucial to distinguish this common, benign finding from the rare but vision-threatening optic neuropathy, which typically presents with a decrease in visual acuity and/or visual field defects. Immediate discontinuation would be an overreaction based on these specific symptoms.

Question 6

A 77-year-old male with severe COPD and heart failure with preserved ejection fraction (HFpEF) is found to have asymptomatic atrial fibrillation on a routine ECG. His heart rate is 95-105 bpm. He is anticoagulated appropriately.

In considering amiodarone for rate control in this patient, the prescriber must weigh the benefit against the significant risk of exacerbating which of his comorbidities?

  1. Heart failure, due to its potent negative inotropic effects.
  2. Renal dysfunction, due to its primary route of elimination.
  3. Pulmonary disease, due to the risk of interstitial pneumonitis. (correct answer)
  4. Hepatic failure, as it is contraindicated in patients with any liver disease.
Explanation: Amiodarone carries a significant risk of pulmonary toxicity, including chronic interstitial pneumonitis, which can be fatal. In a patient with pre-existing severe COPD, this risk is a major concern and must be carefully weighed against the potential benefit. While amiodarone has some negative inotropic effects, it is generally considered safer in heart failure than many other antiarrhythmics. It has minimal renal elimination, so it is safe in renal dysfunction. It can cause hepatotoxicity but is not absolutely contraindicated in all liver disease; it requires close monitoring.

Question 7

A patient in the intensive care unit is being treated for an episode of sustained ventricular tachycardia with an intravenous bolus of amiodarone. Shortly after the infusion begins, the patient's blood pressure drops from 110/70 mmHg to 75/40 mmHg.

This acute hypotensive response is most likely mediated by which of the following?

  1. The negative inotropic effects of amiodarone on the ventricular myocardium.
  2. The vasodilatory properties of the solvent vehicle used in the IV formulation. (correct answer)
  3. An acute, drug-induced destructive thyroiditis causing a thyroid storm.
  4. Profound QTc interval prolongation leading to decreased cardiac output.
Explanation: The acute hypotension seen with intravenous amiodarone infusion is primarily caused by the vasodilatory effects of the solvent vehicles, polysorbate 80 and benzyl alcohol, not by the amiodarone molecule itself. This effect can be mitigated by slowing the infusion rate. While amiodarone does have negative inotropic effects, they are generally modest and not the primary cause of such a rapid and profound drop in blood pressure. Thyroid storm and significant QTc prolongation are not typical acute effects of a loading bolus.

Question 8

A 55-year-old male on long-term amiodarone therapy for atrial fibrillation presents with palpitations, heat intolerance, and a 10-lb weight loss. Laboratory tests reveal a TSH level of <0.01 mIU/L and an elevated free T4. A thyroid ultrasound shows no nodules and normal vascularity.

Which of the following findings would most strongly differentiate amiodarone-induced thyrotoxicosis (AIT) Type 2 from Type 1?

  1. A very low radioiodine uptake (RAIU) value on a thyroid scan. (correct answer)
  2. The presence of anti-thyroid peroxidase (TPO) antibodies.
  3. A rapid symptomatic improvement with high-dose methimazole.
  4. An elevated serum level of interleukin-6 (IL-6).
Explanation: AIT is classified into Type 1 (iodine-induced hyperthyroidism in an abnormal gland) and Type 2 (destructive thyroiditis in a normal gland). The key differentiating feature is thyroid gland function. In Type 1, the gland is actively overproducing hormone, so it will take up iodine. In Type 2, the gland is being destroyed and releasing pre-formed hormone, so it will not take up iodine. Therefore, a very low RAIU is characteristic of Type 2. Anti-TPO antibodies suggest underlying autoimmunity, often seen in Type 1. Rapid response to methimazole (which blocks hormone synthesis) is characteristic of Type 1. While IL-6 is often elevated in Type 2, the RAIU scan is a more definitive and commonly used diagnostic discriminator.

Question 9

A patient taking amiodarone presents with new-onset fatigue and constipation. Lab work reveals a TSH of 12.4 mIU/L (ref 0.4-4.0 mIU/L) and a low-normal free T4. The patient's arrhythmia is well-controlled.

What is the most appropriate management of the patient's thyroid abnormality?

  1. Discontinue amiodarone immediately due to thyroid toxicity.
  2. Reassure the patient and repeat TFTs in 6 months, as this is a transient effect.
  3. Administer a short course of corticosteroids to treat thyroiditis.
  4. Initiate therapy with levothyroxine while continuing amiodarone. (correct answer)
Explanation: When you encounter thyroid abnormalities in patients taking amiodarone, recognize that this antiarrhythmic drug commonly causes both hypothyroidism and hyperthyroidism through its high iodine content and direct thyroid effects. The key is distinguishing between these conditions and managing them appropriately while preserving arrhythmia control. This patient presents with classic hypothyroidism: elevated TSH, low-normal free T4, and symptoms of fatigue and constipation. Since the arrhythmia remains well-controlled, the correct approach is option D - initiate levothyroxine therapy while continuing amiodarone. Amiodarone-induced hypothyroidism responds well to thyroid hormone replacement, and discontinuing amiodarone risks life-threatening arrhythmia recurrence. Option A is wrong because discontinuing amiodarone immediately could destabilize the patient's cardiac rhythm, and hypothyroidism doesn't constitute "thyroid toxicity" requiring urgent drug cessation. Option B incorrectly assumes this is transient - amiodarone-induced hypothyroidism typically persists and requires treatment, not just monitoring. Option C misidentifies the condition as thyroiditis requiring corticosteroids, when this is actually straightforward hypothyroidism needing hormone replacement. Study tip: Remember the "amiodarone dilemma" - this drug causes thyroid problems but is often essential for life-threatening arrhythmias. For hypothyroidism, add levothyroxine and continue amiodarone. Only consider discontinuing amiodarone for hyperthyroidism that's refractory to medical management. Always weigh thyroid risks against cardiac benefits in these scenarios.

Question 10

A patient on chronic amiodarone therapy is undergoing routine monitoring. His liver function tests (LFTs) show an ALT of 110 U/L and an AST of 95 U/L (normal <40 U/L). This is the first time his LFTs have been elevated. The patient is asymptomatic.

What is the most appropriate initial management for this patient?

  1. Discontinue amiodarone immediately and admit the patient for acute liver failure.
  2. Continue amiodarone at the current dose and recheck LFTs in 6 months.
  3. Decrease the dose of amiodarone and recheck LFTs in 2 to 4 weeks. (correct answer)
  4. Order a liver biopsy to stage the extent of drug-induced fibrosis.
Explanation: Asymptomatic elevations in aminotransferases are common with amiodarone therapy. Elevations less than 2-3 times the upper limit of normal can often be managed by reducing the dose. The next appropriate step is to attempt a dose reduction and monitor the LFTs closely to see if they improve. Immediate discontinuation is generally reserved for more severe elevations, symptomatic hepatitis, or signs of hepatic dysfunction. Waiting 6 months is too long, and a liver biopsy is an invasive procedure that is not indicated for an initial, moderate elevation.

Question 11

A 68-year-old female with persistent atrial fibrillation is hemodynamically stable. Her CHA₂DS₂-VASc score is 4. Her physician initiates warfarin therapy and plans to start amiodarone for rhythm control. Her international normalized ratio (INR) is stable at 2.5 on warfarin 5 mg daily.

Upon initiation of a standard oral loading dose of amiodarone, which adjustment to her medication regimen is most appropriate?

  1. Maintain the current warfarin dose and recheck INR in 4 weeks.
  2. Prophylactically decrease the daily warfarin dose by approximately 30-50%. (correct answer)
  3. Increase the daily warfarin dose by 25% to account for increased clot risk during initiation.
  4. Switch from warfarin to apixaban, as no dose adjustment is needed.
Explanation: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. This interaction leads to a significant increase in INR and bleeding risk. The onset of this interaction is within days to a week. The standard of care is to empirically reduce the warfarin dose by 25-50% upon starting amiodarone and to monitor the INR closely (e.g., within 3-5 days). Maintaining the dose is unsafe. Increasing the dose is the opposite of the required action. While switching to a DOAC is an option, it is not a required adjustment, and amiodarone can also inhibit P-glycoprotein, potentially affecting DOAC levels as well, although often to a lesser extent than warfarin.

Question 12

A patient stabilized on amiodarone for atrial fibrillation develops a urinary tract infection and is prescribed a course of levofloxacin.

The co-administration of these two drugs significantly increases the patient's risk for which of the following?

  1. Acute interstitial nephritis and renal failure.
  2. Serotonin syndrome due to monoamine oxidase inhibition.
  3. Torsades de Pointes due to an additive effect on QT interval prolongation. (correct answer)
  4. Hepatotoxicity due to competition for the same metabolic pathway.
Explanation: Both amiodarone and fluoroquinolones (like levofloxacin) are known to prolong the QTc interval on the electrocardiogram. When used concurrently, their effects are additive, which can lead to excessive QT prolongation and significantly increase the risk of the life-threatening ventricular arrhythmia Torsades de Pointes. While both drugs can have other side effects, this pharmacodynamic interaction is the most critical and well-documented concern with their co-administration.

Question 13

A 68-year-old female with persistent atrial fibrillation is hemodynamically stable. Her CHA₂DS₂-VASc score is 4. Her physician initiates warfarin therapy and plans to start amiodarone for rhythm control. Her international normalized ratio (INR) is stable at 2.5 on warfarin 5 mg daily.

Upon initiation of a standard oral loading dose of amiodarone, which adjustment to her medication regimen is most appropriate?

  1. Maintain the current warfarin dose and recheck INR in 4 weeks.
  2. Prophylactically decrease the daily warfarin dose by approximately 30-50%. (correct answer)
  3. Increase the daily warfarin dose by 25% to account for increased clot risk during initiation.
  4. Switch from warfarin to apixaban, as no dose adjustment is needed.
Explanation: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. This interaction leads to a significant increase in INR and bleeding risk. The onset of this interaction is within days to a week. The standard of care is to empirically reduce the warfarin dose by 25-50% upon starting amiodarone and to monitor the INR closely (e.g., within 3-5 days). Maintaining the dose is unsafe. Increasing the dose is the opposite of the required action. While switching to a DOAC is an option, it is not a required adjustment, and amiodarone can also inhibit P-glycoprotein, potentially affecting DOAC levels as well, although often to a lesser extent than warfarin.

Question 14

A patient in the intensive care unit is being treated for an episode of sustained ventricular tachycardia with an intravenous bolus of amiodarone. Shortly after the infusion begins, the patient's blood pressure drops from 110/70 mmHg to 75/40 mmHg.

This acute hypotensive response is most likely mediated by which of the following?

  1. The negative inotropic effects of amiodarone on the ventricular myocardium.
  2. The vasodilatory properties of the solvent vehicle used in the IV formulation. (correct answer)
  3. An acute, drug-induced destructive thyroiditis causing a thyroid storm.
  4. Profound QTc interval prolongation leading to decreased cardiac output.
Explanation: The acute hypotension seen with intravenous amiodarone infusion is primarily caused by the vasodilatory effects of the solvent vehicles, polysorbate 80 and benzyl alcohol, not by the amiodarone molecule itself. This effect can be mitigated by slowing the infusion rate. While amiodarone does have negative inotropic effects, they are generally modest and not the primary cause of such a rapid and profound drop in blood pressure. Thyroid storm and significant QTc prolongation are not typical acute effects of a loading bolus.

Question 15

A patient was treated with amiodarone for 3 years before it was discontinued due to a transition to catheter ablation for his arrhythmia. Six weeks after his last dose, he is prescribed simvastatin 40 mg daily by a different provider. He presents two weeks later with severe myalgias.

What is the most likely explanation for the patient's myalgias?

  1. The patient is experiencing a statin-induced myopathy unrelated to his prior amiodarone use.
  2. An interaction persists because amiodarone and its active metabolite have a very long elimination half-life. (correct answer)
  3. Amiodarone has permanently altered the function of the CYP3A4 enzyme system.
  4. Catheter ablation has altered the patient's metabolism, increasing his sensitivity to statins.
Explanation: Amiodarone and its primary active metabolite, desethylamiodarone (DEA), have extremely long elimination half-lives (amiodarone ~58 days, DEA even longer). Because amiodarone is a potent inhibitor of CYP3A4 (which metabolizes simvastatin), clinically significant concentrations can persist in the body for months after discontinuation. This leads to decreased metabolism of simvastatin, increased systemic exposure, and a higher risk of myopathy. The interaction is not permanent, but it is very prolonged. The recent initiation of the statin after discontinuation of the inhibitor makes the interaction the most probable cause.

Question 16

A patient on chronic amiodarone therapy is undergoing routine monitoring. His liver function tests (LFTs) show an ALT of 110 U/L and an AST of 95 U/L (normal <40 U/L). This is the first time his LFTs have been elevated. The patient is asymptomatic.

What is the most appropriate initial management for this patient?

  1. Discontinue amiodarone immediately and admit the patient for acute liver failure.
  2. Continue amiodarone at the current dose and recheck LFTs in 6 months.
  3. Decrease the dose of amiodarone and recheck LFTs in 2 to 4 weeks. (correct answer)
  4. Order a liver biopsy to stage the extent of drug-induced fibrosis.
Explanation: Asymptomatic elevations in aminotransferases are common with amiodarone therapy. Elevations less than 2-3 times the upper limit of normal can often be managed by reducing the dose. The next appropriate step is to attempt a dose reduction and monitor the LFTs closely to see if they improve. Immediate discontinuation is generally reserved for more severe elevations, symptomatic hepatitis, or signs of hepatic dysfunction. Waiting 6 months is too long, and a liver biopsy is an invasive procedure that is not indicated for an initial, moderate elevation.

Question 17

A 45-year-old man with no other medical history develops paroxysmal atrial fibrillation. He is an avid runner and wants to maintain an active lifestyle. An electrophysiologist is considering rhythm control strategies.

In which scenario would amiodarone be considered an inappropriate first-line choice for this patient?

  1. If the patient also has significant left ventricular hypertrophy.
  2. If the patient has failed a trial of a beta-blocker and flecainide.
  3. If the patient has concomitant heart failure with a low ejection fraction.
  4. Due to his relatively young age and the favorable long-term safety profile of other options. (correct answer)
Explanation: Amiodarone is highly effective but has substantial long-term, cumulative organ toxicity (pulmonary, thyroid, liver, etc.). In a young, otherwise healthy patient, amiodarone is generally reserved as a second or third-line agent after safer alternatives (like flecainide, propafenone, sotalol, or catheter ablation) have been considered or tried. The goal is to avoid decades of exposure to its toxic effects. In contrast, amiodarone is a first-line choice in patients with structural heart disease like significant LVH or HFrEF, where other antiarrhythmics are often contraindicated. It would also be a reasonable choice after failing other agents.

Question 18

A patient on amiodarone 400 mg daily presents for follow-up. He complains of a tremor in his hands, difficulty with balance, and a 'pins and needles' sensation in his feet. These symptoms have been progressing over the last few months.

These findings are most consistent with which amiodarone-related adverse effect?

  1. Dose-related central and peripheral neurotoxicity. (correct answer)
  2. Thyrotoxicosis-induced sympathetic overactivity.
  3. Hypotension-induced cerebral and peripheral hypoperfusion.
  4. Acute extrapyramidal symptoms from dopamine receptor blockade.
Explanation: When encountering amiodarone toxicity questions, focus on the drug's unique pharmacokinetic properties and diverse toxicity profile. Amiodarone has an extremely long half-life (weeks to months) and accumulates in tissues, making toxicity often dose-related and progressive. The constellation of symptoms here—hand tremor, balance difficulties, and peripheral neuropathy ("pins and needles")—represents classic amiodarone neurotoxicity affecting both central and peripheral nervous systems. This toxicity typically develops insidiously over months with chronic dosing, as amiodarone accumulates in neural tissues. The combination of cerebellar dysfunction (balance problems, tremor) and peripheral neuropathy is characteristic of amiodarone's dose-dependent neurotoxic effects, making option A correct. Option B (thyrotoxicosis) would present with different symptoms like palpitations, weight loss, heat intolerance, and anxiety rather than the neurological pattern described. Option C (hypotension-induced hypoperfusion) doesn't explain the specific peripheral neuropathy component and would cause more acute, diffuse symptoms rather than this progressive pattern. Option D (extrapyramidal symptoms) is incorrect because amiodarone doesn't significantly block dopamine receptors, and extrapyramidal symptoms would include rigidity, bradykinesia, and dystonia rather than tremor with balance issues and neuropathy. For amiodarone questions, remember that its toxicities are often dose-related and cumulative due to its pharmacokinetics. Key organs affected include thyroid, lungs, liver, eyes, and nervous system. Always consider the timeline—amiodarone toxicities typically develop gradually over months, not acutely.

Question 19

An 82-year-old resident of a nursing home is on a stable regimen of amiodarone 200 mg daily. Over the past year, the nursing staff has noted a distinctive, slate-gray discoloration of his skin on sun-exposed areas like his face and hands.

This dermatologic finding, while cosmetically displeasing, is primarily the result of which of the following?

  1. An IgE-mediated hypersensitivity reaction to the drug.
  2. A fixed drug eruption that signals impending systemic toxicity.
  3. Chronic subcutaneous bleeding due to platelet dysfunction.
  4. Deposition of lipofuscin and melanin in the dermis. (correct answer)
Explanation: When you encounter dermatologic side effects from chronic drug therapy, especially with distinctive pigmentation changes, you should think about drug-induced tissue deposition rather than acute allergic reactions. The slate-gray discoloration described here is classic amiodarone-induced skin pigmentation, a well-documented adverse effect of long-term therapy. This occurs because amiodarone is highly lipophilic and accumulates in tissues over time. The drug itself, along with its metabolites, gets deposited in the dermis where it stimulates melanin production and forms lipofuscin-like complexes. These deposits create the characteristic blue-gray appearance, particularly in sun-exposed areas where photosensitivity reactions enhance the process. Choice A is incorrect because this isn't an IgE-mediated hypersensitivity reaction. IgE reactions are acute, occurring within minutes to hours, and present as urticaria, angioedema, or anaphylaxis—not chronic pigmentation changes. Choice B mischaracterizes this as a fixed drug eruption. Fixed drug eruptions are localized inflammatory lesions that recur in the same location upon re-exposure to the offending drug, not diffuse pigmentation changes. Choice C incorrectly attributes the discoloration to bleeding. While amiodarone can affect coagulation, the slate-gray appearance isn't from hemosiderin deposits or bruising patterns. Choice D correctly identifies the mechanism: deposition of lipofuscin and melanin in the dermis from chronic amiodarone accumulation. Study tip: Remember that amiodarone has multiple organ toxicities due to its long half-life and tissue accumulation. When you see chronic amiodarone therapy with unusual symptoms, think "deposition and accumulation" rather than acute reactions.

Question 20

A patient stabilized on amiodarone for atrial fibrillation develops a urinary tract infection and is prescribed a course of levofloxacin.

The co-administration of these two drugs significantly increases the patient's risk for which of the following?

  1. Acute interstitial nephritis and renal failure.
  2. Serotonin syndrome due to monoamine oxidase inhibition.
  3. Torsades de Pointes due to an additive effect on QT interval prolongation. (correct answer)
  4. Hepatotoxicity due to competition for the same metabolic pathway.
Explanation: Both amiodarone and fluoroquinolones (like levofloxacin) are known to prolong the QTc interval on the electrocardiogram. When used concurrently, their effects are additive, which can lead to excessive QT prolongation and significantly increase the risk of the life-threatening ventricular arrhythmia Torsades de Pointes. While both drugs can have other side effects, this pharmacodynamic interaction is the most critical and well-documented concern with their co-administration.